following a full submission:
erenumab (Aimovig®) is accepted for restricted use within NHSScotland.
Indication under review: for the prophylaxis of migraine in adults who have at least four migraine days per month.
SMC restriction: patients with chronic migraine and in whom at least three prior prophylactic treatments have failed.
In studies in patients with episodic and chronic migraine, erenumab significantly reduced the number of migraine days per month compared with placebo.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of erenumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
- Medicine name:
- erenumab (Aimovig)
- SMC ID:
- for the prophylaxis of migraine in adults who have at least 4 migraine days per month
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published:
- 08 April 2019